MiMedx Group (MDXG) Price & Analysis

Compare

487 Followers

MDXG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.47 - $10.14

Previous CloseN/A

Volume99.42K

Average Volume (3M)846.54K

Market Cap

$1.06B

Enterprise Value$811.92M

Total Cash (Recent Filing)$106.43M

Total Debt (Recent Filing)$18.66M

Price to Earnings (P/E)33.2

Beta0.76

Next Earnings

Oct 29, 2025

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.06

Shares Outstanding147,959,410

10 Day Avg. Volume518,378

30 Day Avg. Volume846,541

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.77

Enterprise Value/Revenue2.30

Enterprise Value/Gross Profit2.81

Enterprise Value/Ebitda14.78

Forecast

1Y Price Target

$11.13

Price Target Upside55.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Market PositionMDXG continues to grow versus difficult prior-year comparisons, a testament to the company's execution.

Product SalesMDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.

Strategic InitiativesManagement remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.

Bears Say

Market ChallengesPotential $1.0-1.5bn in Medicare Skin Sub payments still up for grabs.

Reimbursement UncertaintyContinuing reimbursement uncertainty disrupted the business in the physician office setting.

MiMedx Group News

MiMedx price target raised to $12 from $11 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight...

29d ago

MDXG

ORGO

MiMedx sees FY25 revenue up low double-digits percent

Sees FY25 adjusted EBITDA margin above 20%. The company said, “Longer-term, the Company continues to expect to achieve...

29d ago

MDXG

MiMedx reports Q2 EPS 6c, consensus 5c

Reports Q2 revenue $98.61M, consensus $90.79M. Joseph Capper, MiMedx (MDXG) CEO, commented, “We are proud to report on...

29d ago

MDXG

MiMedx announces strategic collaboration with Vaporox

MiMedx (MDXG) Group and Vaporox jointly announced a collaboration, whereby the companies will co-promote and co-market their wound...

30d ago

MDXG

MiMedx Group Inc. Reports Record Earnings and Growth

MiMedx Group Inc. (($MDXG)) has held its Q2 earnings call. Read on for the main highlights of the...

28d ago

MDXG

MiMedx Reports Record Q2 2025 Financial Results

MiMedx Group Inc. ( ($MDXG) ) has released its Q2 earnings. Here is a breakdown of the information...

29d ago

MDXG

MiMedx Group Reports Record Q2 2025 Financial Results

The latest announcement is out from MiMedx Group ( ($MDXG) ). MiMedx Group announced record financial results for...

29d ago

MDXG

Video: Why Organogenesis And MiMedx Are Sinking Today

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

1M ago

MDXG

ORGO

MiMedx comments on proposed Medicare reimbursement rule changes

“We welcome and support improvements to Medicare’s reimbursement of skin substitutes across all care settings. The proposed rule,...

1M ago

MDXG

Northland sees ‘key positive’ for MiMedx in CMS rule proposal

Northland analyst Carl Byrnes says the CMS is taking action to curb skin substitute spending with its 2026...

1M ago

MDXG

Organogenesis selloff on CMS proposal ‘may be incorrect,’ says BTIG

BTIG believes the selloff in shares of Organogenesis (ORGO) on the Centers for Medicare and Medicaid Services’ proposed...

1M ago

MDXG

ORGO

Organogenesis, MiMedx fall after CMS rule to cut skin substitutes spending

The Centers for Medicare and Medicaid Services announced a proposed rule “that would increase quality care for Medicare...

2M ago

MDXG

ORGO

MiMedx management to meet with Northland

Meeting to be held on June 26 hosted by Northland. Published first on TheFly – the ultimate source...

2M ago

MDXG

MiMedx Group Holds Annual Shareholder Meeting

MiMedx Group ( ($MDXG) ) has provided an announcement. On June 18, 2025, MiMedx Group held its Annual...

2M ago

MDXG

MDXG FAQ

What was MiMedx Group’s price range in the past 12 months?

MiMedx Group lowest stock price was $5.47 and its highest was $10.14 in the past 12 months.

What is MiMedx Group’s market cap?

MiMedx Group’s market cap is $1.06B.

When is MiMedx Group’s upcoming earnings report date?

MiMedx Group’s upcoming earnings report date is Oct 29, 2025 which is in 61 days.

How were MiMedx Group’s earnings last quarter?

MiMedx Group released its earnings results on Jul 30, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.054 by $0.006.

Is MiMedx Group overvalued?

According to Wall Street analysts MiMedx Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does MiMedx Group pay dividends?

MiMedx Group does not currently pay dividends.

What is MiMedx Group’s EPS estimate?

MiMedx Group’s EPS estimate is 0.06.

How many shares outstanding does MiMedx Group have?

MiMedx Group has 147,959,410 shares outstanding.

What happened to MiMedx Group’s price movement after its last earnings report?

MiMedx Group reported an EPS of $0.06 in its last earnings report, beating expectations of $0.054. Following the earnings report the stock price went up 10.276%.

Which hedge fund is a major shareholder of MiMedx Group?

Currently, no hedge funds are holding shares in MDXG

MiMedx Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

16.62%

Trailing 12-Months

Asset Growth

26.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MiMedx Group

MiMedx Group, Inc. (MDXG) is a biotechnology company focused on the development and commercialization of regenerative medicine products based on human amniotic membrane. The company operates primarily in the healthcare sector, specializing in advanced wound care and surgical biologics. MiMedx's core products include allograft tissue products that are used to treat chronic and acute wounds, as well as surgical applications, aimed at enhancing healing and improving patient outcomes.

MiMedx Group (MDXG) Earnings & Revenues

Historic Earnings Reports

MDXG Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook due to record revenue and EBITDA, strong segment growth, and strategic product developments. However, there are challenges posed by anticipated changes in Medicare reimbursement and slower than expected clinical trial enrollments.View all MDXG earnings summaries

MDXG Stock 12 Month Forecast

Average Price Target

$11.13

▲(55.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","6.25":"$6.25","8.5":"$8.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.25,8.5,10.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.16,7.532307692307692,7.904615384615385,8.276923076923078,8.649230769230769,9.021538461538462,9.393846153846154,9.766153846153847,10.138461538461538,10.510769230769231,10.883076923076922,11.255384615384616,11.627692307692307,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.16,7.4653846153846155,7.770769230769231,8.076153846153847,8.381538461538462,8.686923076923078,8.992307692307692,9.297692307692309,9.603076923076923,9.90846153846154,10.213846153846154,10.51923076923077,10.824615384615385,{"y":11.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.16,7.263076923076923,7.366153846153846,7.469230769230769,7.572307692307692,7.6753846153846155,7.7784615384615385,7.881538461538462,7.984615384615385,8.087692307692308,8.19076923076923,8.293846153846154,8.396923076923077,{"y":8.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >